🟢 United Therapeutics is trading 17.3% up in pre-market — catalyst remains unclear

United Therapeutics is trading 17.3% up in pre-market at $578.54, after rising from the September 21 close of $493.10; the catalyst remains unclear.

• No credible September 22, 2026 company-specific announcement, earnings release, FDA decision, or analyst action was identified.
• Coverage instead references earlier September developments, including the accelerated share repurchase and Tyvaso FDA filing.
• The broader market is only mixed, so macro sentiment does not explain the move; recheck delayed news or a data-quality issue.